University Medical Centre Hamburg-Eppendorf, Institute of Clinical Chemistry, Mass Spectrometric Proteomics, Hamburg, Germany.
PLoS One. 2013 May 28;8(5):e64027. doi: 10.1371/journal.pone.0064027. Print 2013.
In mammalian species, except humans, N-terminal processing of the precursor peptide angiotensin I (ANG-1-10) into ANG-2-10 or ANG-3-10 was reported. Here we hypothesize that aminopeptidase-generated angiotensins bearing the same C-terminus as ANG-1-10 are also present in humans. We demonstrate the time dependent generation of ANG-2-10, ANG-3-10, ANG-4-10, ANG-5-10 and ANG-6-10 from the precursor ANG-1-10 by human plasma proteins. The endogenous presence of ANG-4-10, ANG-5-10 and ANG-6-10 in human plasma was confirmed by an immuno-fluorescence assay. Generation of ANG-2-10, ANG-3-10 and ANG-4-10 from ANG-1-10 by immobilized human plasma proteins was sensitive to the cysteine/serine protease inhibitor antipain. The metal ion chelator EDTA inhibited Ang-6-10-generation. Incubation of the substrates ANG-3-10, ANG-4-10 and ANG-5-10 with recombinant aminopeptidase N (APN) resulted in a successive N-terminal processing, finally releasing ANG-6-10 as a stable end product, demonstrating a high similarity concerning the processing pattern of the angiotensin peptides compared to the angiotensin generating activity in plasma. Recombinant ACE-1 hydrolyzed the peptides ANG-2-10, ANG-3-10, ANG-4-10 and ANG-5-10 into ANG-2-8, ANG-3-8, ANG-4-8 and ANG-5-8. Since ANG-2-10 was processed into ANG-2-8, ANG-4-8 and ANG-5-8 by plasma proteases the angiotensin peptides bearing the same C-terminus as ANG-1-10 likely have a precursor function in human plasma. Our results confirm the hypothesis of aminopeptidase mediated processing of ANG-1-10 in humans. We show the existence of an aminopeptidase mediated pathway in humans that bypasses the known ANG-1-8-carboxypeptidase pathway. This expands the knowledge about the known human renin angiotensin system, showing how efficiently the precursor ANG-1-10 is used by nature.
在哺乳动物物种中,除了人类外,前体肽血管紧张素 I(ANG-1-10)的 N 端加工为 ANG-2-10 或 ANG-3-10 已有报道。在这里,我们假设在人类中也存在与 ANG-1-10 具有相同 C 末端的氨基肽酶生成的血管紧张素。我们证明了人血浆蛋白可使前体 ANG-1-10 生成 ANG-2-10、ANG-3-10、ANG-4-10、ANG-5-10 和 ANG-6-10。通过免疫荧光测定法证实了内源性 ANG-4-10、ANG-5-10 和 ANG-6-10 存在于人血浆中。固定化人血浆蛋白对 ANG-1-10 生成 ANG-2-10、ANG-3-10 和 ANG-4-10 的作用对半胱氨酸/丝氨酸蛋白酶抑制剂抑肽酶敏感。金属离子螯合剂 EDTA 抑制 Ang-6-10 的生成。用重组氨基肽酶 N(APN)孵育底物 ANG-3-10、ANG-4-10 和 ANG-5-10 导致连续的 N 端加工,最终释放 ANG-6-10 作为稳定的终产物,与血浆中的血管紧张素生成活性相比,表明血管紧张素肽的加工模式具有高度相似性。重组 ACE-1 将肽 ANG-2-10、ANG-3-10、ANG-4-10 和 ANG-5-10 水解成 ANG-2-8、ANG-3-8、ANG-4-8 和 ANG-5-8。由于 ANG-2-10 被血浆蛋白酶加工成 ANG-2-8、ANG-4-8 和 ANG-5-8,因此与 ANG-1-10 具有相同 C 末端的血管紧张素肽可能在人血浆中具有前体功能。我们的结果证实了人类中存在氨基肽酶介导的 ANG-1-10 加工的假设。我们证明了人类中存在一种氨基肽酶介导的途径,该途径绕过了已知的 ANG-1-8-羧肽酶途径。这扩展了人们对已知的人类肾素血管紧张素系统的认识,展示了大自然是如何有效地利用前体 ANG-1-10 的。